Skip to main content
Book Chapter

Talimogene Laherparepvec

  • Rotte A
  • Bhandaru M
Springer International Publishing, (2016), 333-347
DOI: 10.1007/978-3-319-48066-4_14
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Talimogene laherparepvec (tal im' oh jeen la her" pa rep' vek), often simply called "T-VEC" is a cancer-killing (oncolytic) virus currently being studied for the treatment of melanoma and other advanced cancers. The drug was initially developed by BioVex, Inc. under the name OncoVEXGM-CSF until it was acquired by Amgen in 2011. With the announcement of positive results in March 2013, T-VEC is the first oncolytic virus to be proven effective in a Phase III clinical trial.

Cite

CITATION STYLE

APA

Rotte, A., & Bhandaru, M. (2016). Talimogene Laherparepvec. In Immunotherapy of Melanoma (pp. 333–347). Springer International Publishing. https://doi.org/10.1007/978-3-319-48066-4_14

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free